CRISPR Therapeutics AG (CRSP) Earnings Call Transcripts
CRISPR Therapeutics AG's Latest Earnings Call - June 9, 2026
In Q2 FY2026, CRISPR Therapeutics AG focused on its strategic shift towards cardiovascular and autoimmune franchises, with significant pipeline developments. The company did not provide specific revenue or earnings figures in the call. However, management highlighted five clinical trial readouts expected in the second half of the year across three programs, which could significantly influence future growth. No changes to guidance were explicitly mentioned, but the company emphasized its robust financial position with over $2.4 billion on the balance sheet, indicating capacity for continued investment in its pipeline.
Reported metrics
| Metric | Value |
|---|---|
| Balance Sheet | $2.4 billion (inline) |
| Clinical Trial Readouts | 5 readouts in H2 2026 (positive) |
| Patient Dosing | Over 14 patients dosed (inline) |
Guidance from management
Management did not provide specific forward guidance figures but emphasized the potential for pivotal trials in 2027 and highlighted the strategic focus on cardiovascular and autoimmune areas.
What management said
Yes. So when we had patients with -- in oncology with CNS involvement, we did see reductions with our first-gen program. So we know that the allogeneic CAR-Ts do cross the blood-brain barrier. I think when we were thinking about strategically where we could -- where an allogeneic CAR-T could benefit patients where a TCE or in vivo CAR-T may not be able to, I think CNS popped up as an area where that could happen beca...
What analysts pressed on
Analysts expressed interest in the competitive landscape for the cardiovascular programs and the strategic decision-making process for prioritizing indications. There were questions about the potential for partnerships and the company's ability to manage broad-based development independently.
Main topics on the call
- Pipeline Developments — CRISPR Therapeutics is focusing on cardiovascular and autoimmune diseases with five clinical trial readouts expected in the second half of 2026. The programs include CTX611, targeting Factor XI, CTX310 for ANGPTL3, and a...
- Financial Position — The company has over $2.4 billion on its balance sheet, providing flexibility for strategic decisions without immediate need for additional fundraising.
- Strategic Focus Shift — CRISPR is strategically shifting towards cardiometabolic and autoimmune therapeutic areas, leveraging its gene editing capabilities and partnerships like the one with Sirius Therapeutics.
- Allogeneic CAR-T Development — The company is advancing its allogeneic CD19 CAR-T program, with over 14 patients dosed and plans for pivotal trials in 2027. Management highlighted potential cost advantages and strategic focus on severe autoimmune indi...
Read the full CRISPR Therapeutics AG transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About CRISPR Therapeutics AG
CRISPR Therapeutics AG (CRSP) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 44 calls on record spanning January 9, 2020 to June 9, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 44 CRISPR Therapeutics AG earnings call transcripts on record, spanning January 9, 2020 to June 9, 2026. Based on this history, CRISPR Therapeutics AG reports quarterly. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- CRSP
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 44
- First call
- January 9, 2020
- Most recent
- June 9, 2026
- Reporting cadence
- quarterly